Drug intelligence / Profile preview

Enhanced Seasonal Influenza Vaccine

Development stage: Unknown
Lead developer: Orlance
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

Orlance's MACH-1™ enhanced seasonal influenza vaccine is designed to offer improved protection against mismatched influenza strains by combining universal and seasonal influenza antigens. The vaccine technology, which originated from the University of Washington, is delivered using Orlance's proprietary MACH-1 platform, a needle-free 'gene gun' that administers DNA or RNA-coated microparticles into the skin. The development of this vaccine is supported by a $3.3 million Fast Track Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

Beyond the preview

Go deeper on Enhanced Seasonal Influenza Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enhanced Seasonal Influenza Vaccine.

Explore the full profile